News
IVBIY
21.00
NaN%
--
Weekly Report: what happened at IVBIY last week (0429-0503)?
Weekly Report · 2d ago
Weekly Report: what happened at IVBIY last week (0422-0426)?
Weekly Report · 04/29 11:58
Weekly Report: what happened at IVBIY last week (0415-0419)?
Weekly Report · 04/22 11:45
Innovent Biologics appoints new oncology medical chief
Innovent Biologics appoints new oncology medical chief. Dr. Nageatte Ibrahim has over 11 years of oncologist industry drug development experience at Merck and GSK. The company is a manufacturer of medicines for the treatment of cancer and other major diseases.
Seeking Alpha · 04/16 07:25
Weekly Report: what happened at IVBIY last week (0408-0412)?
Weekly Report · 04/15 11:36
Weekly Report: what happened at IVBIY last week (0401-0405)?
Weekly Report · 04/08 11:41
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio, A Seattle-Suzhou ADC Biotech, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, for autoimmune and inflammatory dermatologic diseases. Shanghai's Visen Pharma announced plans to stage an IPO on the Hong Kong Exchange.
Seeking Alpha · 04/07 10:30
Weekly Report: what happened at IVBIY last week (0325-0329)?
Weekly Report · 04/01 11:38
Reported Earlier, Innovent Dosed First Participant In Phase 3 Clinical Study Of IBI310 In Combination With Sintilimab For MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Neoshot is the first Phase 3 clinical trial in China to investigate MSI-H/dMMR colon cancer neoadjuvant immunotherapy. The study will evaluate the safety and efficacy of IBI310 combined with sintilimab. The primary endpoints are complete response rate and event-free survival.
Benzinga · 03/27 06:17
Weekly Report: what happened at IVBIY last week (0318-0322)?
Weekly Report · 03/25 11:41
Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Novo Nordisk announced plans to invest $556 million to expand its Tianjin production facility. BeiGene was approved to market a new drug in the US.
Seeking Alpha · 03/24 11:15
Innovent Biologics reports FY results
Seeking Alpha · 03/21 16:23
Weekly Report: what happened at IVBIY last week (0311-0315)?
Weekly Report · 03/18 11:39
Weekly Report: what happened at IVBIY last week (0304-0308)?
Weekly Report · 03/11 11:35
Week In Review: EurekaBio Raises $40M To Support Lentiviral Vector Platform
Shenzhen EurekaBio closed a $40 million Series B+ funding to support the commercialization of its Lentiviral Vector Production System. Chengdu Maxvax Biotechnology raised $40M in a Series C financing round to advance its portfolio of seven vaccines. Hangzhou Zylox-Tonbridge entered a $15 million deal to distribute and manufacture the entire device line of California's Avinger in China.
Seeking Alpha · 03/10 07:55
Weekly Report: what happened at IVBIY last week (0226-0301)?
Weekly Report · 03/04 11:39
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412M Deal
Seeking Alpha · 03/03 06:35
Innovent Announces First Participant Dosed In A Phase I Study Of IBI3002 In Australia
First participant has been dosed in Australia in a first-in-human phase 1 clinical trial of IBI3002. The first participant is in the first phase 1 trial of a new antibody. Innovent Biologics is a world-class biopharmaceutical company.
Benzinga · 03/01 07:20
Weekly Report: what happened at IVBIY last week (0219-0223)?
Weekly Report · 02/26 11:55
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
Seeking Alpha · 02/25 10:00
More
Webull provides a variety of real-time IVBIY stock news. You can receive the latest news about Innovent Biologi through multiple platforms. This information may help you make smarter investment decisions.
About IVBIY
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.